샘플 요청 목록

 카트 문의
시장보고서
상품코드
1784041

세계의 당뇨병 전증 시장

Prediabetes
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 287 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

당뇨병 전증 세계 시장은 2030년까지 2억 9,130만 달러에 달할 전망

2024년에 2억 1,010만 달러로 추정되는 당뇨병 전증 세계 시장은 2030년에는 2억 9,130만 달러에 달하고, 분석 기간인 2024-2030년 CAGR은 5.6%로 성장할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 디구아니드 약물은 CAGR 7.2%를 기록하며 분석 기간 종료시에는 7,810만 달러에 달할 것으로 예측됩니다. 티아졸리딘계 약물 부문의 성장률은 분석 기간 동안 CAGR 4.1%로 추정됩니다.

미국 시장은 5,730만 달러로 추정, 중국은 CAGR 9.1%로 성장할 것으로 예측

미국의 당뇨병 전증 시장은 2024년에 5,730만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간 2024년부터 2030년까지 CAGR 9.1%로 성장하여 2030년에는 예측 시장 규모 5,950만 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.6%와 5.6%로 예측됩니다. 유럽에서는 독일이 CAGR 3.6%로 성장할 것으로 예측됩니다.

세계 당뇨병 전증 시장 - 주요 동향 및 촉진요인 정리

당뇨병 전증 환자가 공중보건의 주요 관심사가 되고 있는 이유는 무엇일까?

당뇨병 전증은 제2형 당뇨병의 임계치에 도달하지 않은 혈당 상승을 특징으로 하는 질환으로, 전 세계 보건의 큰 도전과제로 떠오르고 있습니다. 생활습관의 변화, 식생활의 변화, 비만율의 증가가 대사 이상에 대한 원인으로 작용하고 있으며, 당뇨병 전증의 유병률은 무서운 속도로 증가하고 있습니다. 당뇨병 전증 환자는 조기에 개입하지 않으면 제2형 당뇨병, 심혈관질환 및 기타 대사성 합병증 발병 위험이 현저히 높아집니다. 이 질환은 무증상인 경우가 많아 진단이 늦어지거나 치료가 지연되어 질병 진행의 위험을 높입니다. 정부와 의료 기관은 증가하는 당뇨병 전증 환자의 부담을 줄이기 위해 조기 검진 프로그램과 생활습관 중재 이니셔티브에 우선순위를 두고 있습니다. 또한, 연속 혈당 모니터링(CGM), 웨어러블 건강 기술, AI 기반 예측 분석의 발전으로 조기 발견 및 개인화된 관리 전략이 가능해졌습니다. 헬스케어 시스템이 예방의학으로 전환되는 가운데, 당뇨병 전증 환자 관리는 전 세계 당뇨병 예방 전략의 핵심 분야로 떠오르고 있습니다.

당뇨병 전증 환자의 효과적인 관리를 방해하는 요인은 무엇일까?

이러한 인식의 증가에도 불구하고, 당뇨병 전증의 효과적인 관리와 예방을 방해하는 몇 가지 문제들이 있습니다. 가장 큰 장벽 중 하나는 정기적인 스크리닝이 이루어지지 않는다는 점입니다. 중저소득 국가에서는 저렴한 진단 도구와 일차 의료 서비스에 대한 접근성이 제한되어 있어 이 문제를 더욱 악화시키고 있습니다. 또한, 식이요법, 운동, 체중 관리 등 생활습관 개선 프로그램에 대한 환자의 순응도는 행동적, 사회경제적 요인으로 인해 여전히 큰 도전 과제입니다. 또한, 표준화된 당뇨병 전증 치료 가이드라인이 없기 때문에 의료 권고에 일관성이 없어 의료 서비스 제공자가 통일된 예방 전략을 시행하는 데 어려움이 있습니다. 또한, 제약 업계는 아직 당뇨병 전증 환자에 특화된 널리 받아들여지는 약리학적 개입을 개발하지 못했으며, 대부분의 치료 접근법은 생활습관 개선이나 당뇨병 치료제의 적응증 외 사용에 의존하고 있습니다. 이러한 문제를 해결하기 위해서는 공중보건 노력, 환자 교육 개선, 장기적인 순응도 및 질병 예방을 강화하기 위한 디지털 헬스 솔루션의 통합이 결합되어야 합니다.

디지털 헬스 및 AI의 혁신은 당뇨병 전증 관리를 어떻게 변화시킬 것인가?

기술의 발전은 당뇨병 전증 환자 관리에 혁명을 가져왔으며, 조기 발견, 모니터링, 개별화된 개입을 위한 혁신적인 솔루션을 제공하고 있습니다. AI를 활용한 예측 모델을 통해 의료진은 유전적, 대사적, 생활습관적 요인에 따라 제2형 당뇨병 발병 위험이 높은 개인을 식별할 수 있습니다. 웨어러블 혈당 측정기, 피트니스 트래커, 모바일 헬스(모바일 헬스) 애플리케이션의 통합으로 혈당, 신체 활동, 식습관에 대한 실시간 데이터를 제공하여 환자가 능동적인 조치를 취할 수 있도록 돕습니다. 행동 코칭과 AI 기반 인사이트를 결합한 디지털 테라피는 개인화된 생활습관 권장사항과 습관 형성 중재를 제공함으로써 당뇨병 전증 환자 관리에서 인기를 끌고 있습니다. 또한, 원격의료는 의료 전문가에 대한 접근성을 확대하고, 특히 의료 서비스가 부족한 지역에서 당뇨병 전증 환자의 원격 모니터링과 진찰을 가능하게 합니다. 디지털 헬스 기술이 발전함에 따라 당뇨병 전증 관리는 데이터 중심의 환자 중심 접근 방식으로 전환되어 조기 개입 전략을 개선하고 질병 진행률을 낮추고 있습니다.

당뇨병 전증 환자 시장 성장의 원동력은?

당뇨병 유병률 증가, 조기 발견 솔루션에 대한 수요 증가, 디지털 헬스 기술의 발전 등 여러 가지 요인에 의해 당뇨병 전증 시장의 성장이 촉진되고 있습니다. 예방적 헬스케어와 조기 개입을 중시하는 경향이 강해지면서 스크리닝 프로그램, 웨어러블 건강 기기, AI 기반 진단에 대한 투자가 활발해지고 있습니다. 제약사들은 당뇨병 전증 환자들을 타겟으로 한 치료법을 개발하기 위해 새로운 치료 전략을 모색하고 있으며, 시장 기회는 더욱 확대되고 있습니다. 또한, 당뇨병 관리와 관련된 장기적인 의료비 절감에 대한 조직의 집중으로 인해 고용주가 후원하는 웰니스 프로그램과 생활습관 개선 이니셔티브에 대한 보험 혜택이 증가함에 따라 시장 성장에 기여하고 있습니다. 또한, 당뇨병 예방에 대한 인식 개선 캠페인과 의료비 보조금을 통한 정부의 노력도 검진 및 생활습관 개선 프로그램 도입률을 높이고 있습니다. 전 세계 헬스케어 환경이 맞춤형 의료와 예방 의료로 전환되는 가운데, 당뇨병 전증 시장은 크게 확대되어 초기 대사성 질환 관리의 혁신을 촉진할 것으로 예상됩니다.

부문

약물 종류(디구아니드 약물, 티아졸리딘계 약물, 글루카곤 유사 펩타이드-1 작용제, SGLT2 억제제, DPP-4 억제제, 기타 약물 종류), 연령층(성인, 노인, 소아)

조사 대상 기업 사례

  • Abbott Laboratories
  • Aphaia Pharma
  • AstraZeneca PLC
  • Boston Therapeutics
  • Caelus Health
  • CH Boehringer Sohn AG & Co KG
  • Corcept Therapeutics
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals Limited
  • HighTide Biopharma Pty Ltd
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Omada Health
  • Pfizer Inc.
  • RESVERLOGIX
  • SciMar Ltd.
  • Takeda Pharmaceutical Company Limited
  • Valbiotis

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.08.11

Global Prediabetes Market to Reach US$291.3 Million by 2030

The global market for Prediabetes estimated at US$210.1 Million in the year 2024, is expected to reach US$291.3 Million by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Diguanide Drugs, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$78.1 Million by the end of the analysis period. Growth in the Thiazolidinediones Drugs segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$57.3 Million While China is Forecast to Grow at 9.1% CAGR

The Prediabetes market in the U.S. is estimated at US$57.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$59.5 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Prediabetes Market - Key Trends & Drivers Summarized

Why Is Prediabetes Becoming a Major Public Health Concern?

Prediabetes, a condition characterized by elevated blood sugar levels that have not yet reached the threshold for type 2 diabetes, is emerging as a major global health challenge. With lifestyle changes, poor dietary habits, and increasing obesity rates contributing to metabolic disorders, the prevalence of prediabetes is rising at an alarming rate. Individuals with prediabetes are at a significantly higher risk of developing type 2 diabetes, cardiovascular diseases, and other metabolic complications if intervention measures are not implemented early. The condition is often asymptomatic, leading to underdiagnosis and delayed treatment, which exacerbates the risk of disease progression. Governments and healthcare organizations are prioritizing early screening programs and lifestyle intervention initiatives to curb the growing burden of prediabetes. Additionally, advances in continuous glucose monitoring (CGM), wearable health technologies, and AI-driven predictive analytics are enabling earlier detection and personalized management strategies. As healthcare systems shift toward preventive medicine, prediabetes management is becoming a key focus area in diabetes prevention strategies worldwide.

What Challenges Are Hindering the Effective Management of Prediabetes?

Despite increasing awareness, several challenges hinder the effective management and prevention of prediabetes. One of the biggest barriers is the lack of routine screening, as many individuals remain undiagnosed until the condition progresses to type 2 diabetes. Limited access to affordable diagnostic tools and primary healthcare services in low- and middle-income countries further exacerbates the issue. Additionally, patient adherence to lifestyle modification programs, including diet, exercise, and weight management, remains a significant challenge due to behavioral and socio-economic factors. The absence of standardized prediabetes treatment guidelines also creates inconsistencies in medical recommendations, making it difficult for healthcare providers to implement uniform prevention strategies. Moreover, the pharmaceutical industry has yet to develop a widely accepted pharmacological intervention specifically for prediabetes, with most treatment approaches relying on lifestyle modifications and off-label use of diabetes medications. Addressing these challenges requires a combination of public health initiatives, improved patient education, and integration of digital health solutions to enhance long-term adherence and disease prevention.

How Are Innovations in Digital Health and AI Transforming Prediabetes Management?

Technological advancements are revolutionizing the management of prediabetes, offering innovative solutions for early detection, monitoring, and personalized intervention. AI-powered predictive models are enabling healthcare providers to identify individuals at high risk of developing type 2 diabetes based on genetic, metabolic, and lifestyle factors. The integration of wearable glucose monitors, fitness trackers, and mobile health (mHealth) applications is providing real-time data on blood sugar levels, physical activity, and dietary habits, empowering patients to take proactive measures. Digital therapeutics, which combine behavioral coaching with AI-driven insights, are gaining traction in prediabetes management, offering personalized lifestyle recommendations and habit-forming interventions. Additionally, telemedicine is expanding access to healthcare professionals, allowing remote monitoring and consultations for prediabetic patients, particularly in underserved regions. With advancements in digital health technology, prediabetes management is shifting toward a more data-driven, patient-centric approach, improving early intervention strategies and reducing disease progression rates.

What Is Driving the Growth of the Prediabetes Market?

The growth in the prediabetes market is driven by several factors, including rising diabetes prevalence, increasing demand for early detection solutions, and advancements in digital health technology. The growing emphasis on preventive healthcare and early intervention is fueling investments in screening programs, wearable health devices, and AI-driven diagnostics. Pharmaceutical companies are exploring novel therapeutic strategies to develop targeted treatments for prediabetes, further expanding market opportunities. The rise of employer-sponsored wellness programs and insurance incentives for lifestyle modification initiatives is also contributing to market growth, as organizations focus on reducing long-term healthcare costs associated with diabetes management. Additionally, government initiatives promoting diabetes prevention through public awareness campaigns and healthcare subsidies are accelerating adoption rates for prediabetes screening and lifestyle intervention programs. As the global healthcare landscape shifts toward personalized and preventive medicine, the prediabetes market is expected to expand significantly, driving innovation in early-stage metabolic disease management.

SCOPE OF STUDY:

The report analyzes the Prediabetes market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs, Other Drug Classes); Age Group (Adults, Elderly, Children)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Abbott Laboratories
  • Aphaia Pharma
  • AstraZeneca PLC
  • Boston Therapeutics
  • Caelus Health
  • CH Boehringer Sohn AG & Co KG
  • Corcept Therapeutics
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals Limited
  • HighTide Biopharma Pty Ltd
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Omada Health
  • Pfizer Inc.
  • RESVERLOGIX
  • SciMar Ltd.
  • Takeda Pharmaceutical Company Limited
  • Valbiotis

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Prediabetes - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Burden of Lifestyle Diseases Throws the Spotlight on Early-Stage Metabolic Disorders
    • Growing Public Health Focus on Diabetes Prevention Drives Adoption of Prediabetes Screening Programs
    • Increasing Prevalence of Obesity and Sedentary Lifestyles Spurs Growth in At-Risk Population Segments
    • Integration of Digital Health Platforms Strengthens Business Case for Scalable Prediabetes Management Solutions
    • Expansion of Remote Patient Monitoring Technologies Accelerates Demand for Continuous Glucose Tracking
    • Advancements in Predictive Analytics and Risk Stratification Tools Drive Early Detection and Intervention
    • Government-Led Awareness Campaigns and Health Screenings Propel Growth in Preemptive Diagnostics
    • Emergence of Mobile Apps and Virtual Coaching Programs Expands Addressable Market for Lifestyle Interventions
    • Rising Consumer Demand for Personalized Nutrition and Wellness Drives Innovation in Preventive Therapies
    • Growth in Employer-Sponsored Wellness Programs Strengthens Preventive Care Access for Working Adults
    • Increased Investment in Non-Invasive Biomarker Research Generates Opportunities for Early Diagnosis
    • Development of Integrated Care Models Drives Adoption of Multidisciplinary Prediabetes Management Pathways
    • Expansion of Digital Therapeutics for Metabolic Syndrome Accelerates Evidence-Based Behavioral Modification
    • Growing Insurance Coverage for Preventive Health Services Spurs Uptake of Prediabetes Screening and Counseling
    • Emergence of AI-Based Decision Support Systems Enhances Clinical Accuracy in Prediabetes Risk Profiling
    • Heightened Focus on Ethnic and Genetic Risk Factors Expands Market for Population-Specific Prevention Strategies
    • Regulatory Encouragement for Chronic Disease Prevention Strengthens Funding for Early-Intervention Programs
    • Adoption of Real-World Evidence Frameworks Drives Longitudinal Studies in Prediabetes Outcome Analysis
    • Rise of Hybrid Healthcare Delivery Models Expands Access to Rural and Underserved Populations
    • Growing Pipeline of Early-Stage Metabolic Therapeutics Drives Innovation in Pharmacological Prevention
    • Expansion of Interoperable Health IT Systems Supports Data Integration Across Prediabetes Care Continuum
    • Challenges in Long-Term Behavioral Adherence Create Market Demand for Engagement-Driven Digital Tools
    • Increased Emphasis on Social Determinants of Health Spurs Community-Based Prediabetes Prevention Initiatives
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Prediabetes Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Prediabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Prediabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Prediabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Diguanide Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Diguanide Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Diguanide Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Thiazolidinediones Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Thiazolidinediones Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Thiazolidinediones Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Glucagon-like Peptide-1 Agonists Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Glucagon-like Peptide-1 Agonists Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Glucagon-like Peptide-1 Agonists Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for SGLT2 Inhibitors Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for SGLT2 Inhibitors Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for SGLT2 Inhibitors Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for DPP-4 Inhibitors Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for DPP-4 Inhibitors Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for DPP-4 Inhibitors Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Adults by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Elderly by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Elderly by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Elderly by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Children by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Children by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Children by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • JAPAN
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • CHINA
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • EUROPE
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Prediabetes by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Prediabetes by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Prediabetes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • FRANCE
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • GERMANY
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Prediabetes by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Prediabetes by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Prediabetes by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • INDIA
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Prediabetes by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Prediabetes by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Prediabetes by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Prediabetes by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Prediabetes by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Prediabetes by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030
  • AFRICA
    • Prediabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Prediabetes by Drug Class - Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Prediabetes by Drug Class - Percentage Breakdown of Value Sales for Diguanide Drugs, Thiazolidinediones Drugs, Glucagon-like Peptide-1 Agonists Drugs, SGLT2 Inhibitors Drugs, DPP-4 Inhibitors Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Prediabetes by Age Group - Adults, Elderly and Children - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Prediabetes by Age Group - Adults, Elderly and Children Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Prediabetes by Age Group - Percentage Breakdown of Value Sales for Adults, Elderly and Children for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제